ESG & Sustainability

Samsung C&T announces new leadership
Samsung C&T on Dec. 7 announced regular presidential appointments for 2023, as it promoted two new leaders. Vice President of Samsung Electronics’ Business Support T/F Jeong HaiLin has been promoted as President and CEO of Samsung C&T Resort Group and concurrently as CEO of Samsung Welstory, while Kang Byung-il, Executive

Samsung C&T seeks 2050 Net Zero
Plan to achieve 2050 Net Zero – Achieve 100% renewable energy by 2030 and net zero carbon emissions by 2050 ⦁ Implement solar repowering to Samsung C&T’s solar power plant in Gimcheon to increase efficiency (up to twofold increase in power generation) ⦁ Obtain overseas renewable energy certificates and domestic

Samsung C&T Q3 2022 earnings
Overall Performance Revenue: KRW 11.256T, up KRW 2.953T (35.6%↑) from KRW 8.303T in Q3 2021 Operating Profit: KRW 797B, up KRW 656B (465.2%↑) from KRW 141B in Q3 2021 In Q3, revenue and operating profit both rose year-over-year (yoy) on the back of balanced growth among the business groups and

Samsung C&T Q2 2022 earnings
Overall Performance Revenue: KRW 10.819T, up KRW 2.271T (26.6%↑) from KRW 8.548T in Q2 2021 Operating Profit: KRW 556B, up KRW 131B (30.8%↑) from KRW 425B in Q2 2021 Despite the adverse business environment, Samsung C&T’s overall revenue and operating profit in Q2 grew as the company’s efforts to improve

Samsung C&T Q1 2022 earnings
Overall Performance Revenue: KRW 10.44T, up KRW 2.6T (33.2%↑) from KRW 7.84T in Q1 2021 Operating Profit: KRW 542B, up KRW 239B (78.9%↑) from KRW 303B in Q1 2021 In Q1, both revenue and operating profit improved as Samsung C&T’s efforts to improve its business fundamentals and competitiveness came to

Samsung Life Science Fund makes first investment in US biotech firm Jaguar Gene Therapy
Gene therapy selected as Samsung Life Science Fund’s first investment choice Jaguar Gene Therapy’s core tech aims to enhance adeno-associated virus (AAV) capsid purity Samsung will collaborate on manufacturing and developing assets with Jaguar Gene Therapy as a strategic investor Samsung will invest in Jaguar Gene Therapy in order to